| dc.description.abstract | Liver cirrhosis is a liver structure that results in the liver not being able to work with the 14th death rank in the world. Treatment of liver cirrhosis is intended for the treatment of complications, comorbidities and limited therapeutic efficacy data after treatment is given. The purpose of this study was to determine the patients, and the efficacy of lactulose combination therapy in liver cirrhosis complications in the inpatient installation of Dr. Sardjito Yogyakarta. Method: the study was conducted observationally with a case-series design. Observation and truth of prospective data were obtained from inpatient status during June-September 2016, the number of 28 patients in the study, 4 other patients were excluded. The results of most liver cirrhosis patients during the study were men (71.43%), 46-55 (28.57%), risk factors for hepatitis B (50%), complications of hepatic encephalopathy (33.33%), disease gastrointestinal group (25.23%), child-pugh C criteria (32.14%), decreased albumin (16.87%). Efficacy of lactulose therapy in hepatic complications improved encephalopathy 71.43%; propranolol and lactulose in esophageal varices improved 100% bleeding defects; spironolactone, furosemide, and albumin in ascites improve 66.67%; propranolol in portal hypertension is 100% cured; lactulose, LOLA, and vitamin K in hepatic encephalopathy repair 100% esophageal varices; propranolol and lactulose in esophageal varices and portal hypertension improve 100%. Conclusion: The combination of Lactulose with propranolol provides 100% efficacy in variations in esophageal vaccine and portal esophageal portal hypertension. The combination of lactulose, LOLA, vitamin K has 100% efficacy in repairing esophageal varices. The combination of Lactulose and propanolol has a 100% efficacy on the portal of esophageal varices and hypertension. | en_US |
